Interestingly, FGF21 has recently been shown to have both antihypertrophic and cardioprotective actions [47,48], and has been considered as a promising new therapy target obesity and associated diseases, by activating BAT and by acting on WAT and the liver [49]. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.